REGNÂ – Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.REGN
$493.22Name : Regeneron Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $53,250,498,560.00
EPSttm : 39.36
Regeneron Pharmaceuticals, Inc.
$493.22
2.10%$10.15Float Short %
2.69
Margin Of Safety %
68
Put/Call OI Ratio
0.79
EPS Next Q Diff
0.95
EPS Last/This Y
-5.55
EPS This/Next Y
4.76
Price
492.86
Target Price
741.76
Analyst Recom
1.67
Performance Q
-30.29
Relative Volume
1.15
Beta
0.31
Ticker: REGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-08 | REGN | 547.3 | 1.00 | 1.06 | 47429 |
| 2025-05-09 | REGN | 527.4 | 0.97 | 0.50 | 48253 |
| 2025-05-12 | REGN | 575.96 | 0.93 | 0.19 | 48666 |
| 2025-05-13 | REGN | 574.01 | 0.95 | 7.81 | 48285 |
| 2025-05-14 | REGN | 571.45 | 0.99 | 2.00 | 50484 |
| 2025-05-15 | REGN | 585.24 | 0.90 | 0.27 | 49616 |
| 2025-05-16 | REGN | 594.31 | 0.87 | 0.45 | 50788 |
| 2025-05-19 | REGN | 596.45 | 0.83 | 1.18 | 42307 |
| 2025-05-20 | REGN | 614.78 | 0.84 | 0.83 | 43191 |
| 2025-05-21 | REGN | 604.65 | 0.84 | 1.43 | 43706 |
| 2025-05-22 | REGN | 596.65 | 0.85 | 4.64 | 44298 |
| 2025-05-23 | REGN | 588.61 | 0.85 | 2.72 | 44392 |
| 2025-05-27 | REGN | 603.11 | 0.83 | 1.09 | 43325 |
| 2025-05-28 | REGN | 591.43 | 0.82 | 0.82 | 43933 |
| 2025-05-29 | REGN | 605.21 | 0.84 | 0.70 | 46698 |
| 2025-05-30 | REGN | 489.98 | 0.84 | 0.99 | 47995 |
| 2025-06-02 | REGN | 490.5 | 0.79 | 1.37 | 53169 |
| 2025-06-03 | REGN | 487.99 | 0.79 | 3.30 | 55248 |
| 2025-06-04 | REGN | 484.93 | 0.81 | 0.98 | 57301 |
| 2025-06-05 | REGN | 482.59 | 0.80 | 1.36 | 57840 |
| 2025-06-06 | REGN | 493.12 | 0.79 | 2.38 | 58490 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-08 | REGN | 547.17 | -26.4 | -1380.8 | 35.79 |
| 2025-05-09 | REGN | 527.17 | -26.4 | -1434.6 | 35.79 |
| 2025-05-12 | REGN | 575.63 | -26.4 | -903.2 | 35.79 |
| 2025-05-13 | REGN | 574.16 | -26.4 | -1289.9 | 35.79 |
| 2025-05-14 | REGN | 571.35 | -26.4 | -1299.6 | 35.79 |
| 2025-05-15 | REGN | 584.75 | -26.6 | -1182.5 | 35.79 |
| 2025-05-16 | REGN | 594.50 | -26.6 | -1212.4 | 35.50 |
| 2025-05-19 | REGN | 596.54 | -26.6 | -1264.0 | 35.50 |
| 2025-05-20 | REGN | 614.79 | -26.6 | -1153.6 | 35.50 |
| 2025-05-21 | REGN | 604.89 | -26.6 | -1345.4 | 35.50 |
| 2025-05-22 | REGN | 596.73 | -26.6 | -1332.9 | 35.50 |
| 2025-05-23 | REGN | 588.18 | -26.6 | -1339.1 | 35.50 |
| 2025-05-27 | REGN | 603.26 | -26.6 | -1174.9 | 35.50 |
| 2025-05-28 | REGN | 592.09 | -26.6 | -1355.4 | 35.50 |
| 2025-05-29 | REGN | 605.03 | -26.6 | -1187.7 | 35.50 |
| 2025-05-30 | REGN | 490.28 | -26.6 | -2060.3 | 35.50 |
| 2025-06-02 | REGN | 490.51 | -26.2 | -1277.4 | 35.50 |
| 2025-06-03 | REGN | 487.86 | -26.2 | -1304.6 | 35.47 |
| 2025-06-04 | REGN | 484.93 | -26.2 | -1197.6 | 35.47 |
| 2025-06-05 | REGN | 483.07 | -26.2 | -1188.2 | 35.47 |
| 2025-06-06 | REGN | 492.86 | -26.2 | -1083.9 | 35.35 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-08 | REGN | 0.00 | 1.34 | 2.50 |
| 2025-05-09 | REGN | 0.00 | 1.34 | 2.50 |
| 2025-05-12 | REGN | 0.00 | 1.93 | 2.77 |
| 2025-05-13 | REGN | 0.00 | 1.93 | 2.77 |
| 2025-05-14 | REGN | 0.00 | 1.93 | 2.77 |
| 2025-05-15 | REGN | 0.00 | 1.93 | 2.77 |
| 2025-05-16 | REGN | 0.00 | 1.93 | 2.77 |
| 2025-05-19 | REGN | 0.00 | 3.63 | 2.77 |
| 2025-05-20 | REGN | 0.00 | 3.63 | 2.77 |
| 2025-05-21 | REGN | 0.00 | 3.63 | 2.77 |
| 2025-05-22 | REGN | 0.00 | 3.63 | 2.77 |
| 2025-05-23 | REGN | 0.00 | 3.63 | 2.77 |
| 2025-05-27 | REGN | 0.00 | -0.96 | 2.77 |
| 2025-05-28 | REGN | 0.00 | -0.96 | 2.69 |
| 2025-05-29 | REGN | 0.00 | -0.96 | 2.69 |
| 2025-05-30 | REGN | 0.00 | -0.96 | 2.69 |
| 2025-06-02 | REGN | 0.00 | -0.39 | 2.69 |
| 2025-06-03 | REGN | 0.00 | -0.39 | 2.69 |
| 2025-06-04 | REGN | 0.00 | -0.39 | 2.69 |
| 2025-06-05 | REGN | 0.00 | -0.39 | 2.69 |
| 2025-06-06 | REGN | 0.00 | -0.39 | 2.69 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
8.22
Avg. EPS Est. Current Quarter
8.53
Avg. EPS Est. Next Quarter
9.17
Insider Transactions
Institutional Transactions
-0.39
Beta
0.31
Average Sales Estimate Current Quarter
3296
Average Sales Estimate Next Quarter
3440
Fair Value
826.14
Quality Score
99
Growth Score
75
Sentiment Score
2
Actual DrawDown %
59.3
Max Drawdown 5-Year %
-59.8
Target Price
741.76
P/E
12.55
Forward P/E
12.48
PEG
9.51
P/S
3.78
P/B
1.82
P/Free Cash Flow
17.17
EPS
39.29
Average EPS Est. Cur. Y​
35.35
EPS Next Y. (Est.)
40.11
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
31.94
Relative Volume
1.15
Return on Equity vs Sector %
-8.7
Return on Equity vs Industry %
9.2
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.44
EBIT Estimation
-1083.9
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15158
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
stock quote shares REGNÂ – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGNÂ – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGNÂ – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGNÂ – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading